South Africa: ARIPO Developments: Amended Harare Protocol On Patents And Industrial Designs

Last Updated: 6 February 2017
Article by Joanne van Harmelen

Most Read Contributor in South Africa, December 2017

The African Regional Intellectual Property Organization's ("ARIPO's") amended Harare Protocol on Patents and Industrial Designs (the "Protocol"), came into effect on 1 January 2017 and includes some important changes.

Most pertinent of these, for those who choose ARIPO as a filing vehicle in Africa, is that it is now compulsory to request substantive examination for ARIPO patent applications. A provision for restoration or re-establishment of rights has also been included. The introduction of new fees and the hiking of application and renewal fees, which, while perhaps necessary to ensure that ARIPO continues to develop systems and improve efficiencies, will not be popular with applicants. However, the amendments do clarify provisions on patentable inventions, restrictions on biotech inventions and multiple dependencies of claims, which are largely welcome. Below, we look at some of these amendments in more detail.

Substantive examination

A request for substantive examination is now required to be filed for every ARIPO patent application, and patent applications will only undergo substantive examination once the examination fee has been paid and the request for examination has been lodged.

The deadline for filing the request for substantive examination is within three years of the earliest priority date, or of the filing date where no priority is claimed. Where no request and payment of the examination fee is made within the prescribed period, the application will lapse.

Reestablishment of rights

Another development is the inclusion of a provision relating to the reestablishment of rights or restoration. This provides for an applicant or proprietor of an ARIPO patent, utility model or industrial design, who, in spite of all due care required by the circumstances having been taken, was unable to observe a time limit set by the Protocol.

In such circumstances, the applicant or proprietor can file a request and pay the prescribed fee to have his/her rights re-established. Such a request must be filed in writing within two months of the removal of the cause of non-compliance and, at the latest, no more than one year from the expiry of the unobserved time limit. However, in the case of the deadlines for claiming priority specified in the Protocol, the request must be filed within two months of the expiry of that period.

An important condition for such a request to be granted is that the non-observance of the time limit must have a direct consequence of causing the refusal of the ARIPO application or of a request, or the deeming of the application to have been withdrawn, or the loss of any other right or means of redress. Once granted, the re-establishment of rights is to be published in the ARIPO Journal.

The Protocol also provides for the consequences, should such a restoration of rights be granted, for a third party who has, in good faith, used or made effective and serious preparations for using an invention or design in the period between the loss of rights and the publication in the ARIPO Journal of the mention of re-establishment of those rights. Such a person may, without payment, continue such use in the course of his/her business or for the needs thereof.

Limitation of an ARIPO patent, post grant (post-grant amendment)

A new section has been introduced into the Protocol that specifically regulates the amendment post-grant of an ARIPO patent. Such an amendment may be applied for from the ARIPO office in writing and on payment of the limitation fee. The amendment must fall wholly within the scope of the claims before amendment.

Claim drafting provisions

Rule 7 has been introduced to provide requirements for drafting method of treatment claims and multiple dependent claims:

  1. "Claims regarded as first medical indications

    1. Pharmaceutical composition for the prophylaxis/treatment of Y(=disease) comprising X(=a drug/medicament).
    2. Pharmaceutical composition comprising X.
    3. Compound X for use as a drug/medicament for the treatment of Y.
    4. Use of X for the manufacture of a pharmaceutical composition (Note that the disease indication is not mentioned in the claim).
    5. Compound X for use as an analgesic.
    6. Compound X for use in treating disease Y.
    7. Compound A containing X for use in treating disease Y (composition A may be genetically defined).
    8. Medicament containing compound X.
    9. Use of X for preparing a medicament.
  2. Claims regarded as second medical indications

    1. Use of X for the manufacture/preparation of a medicament/pharmaceutical composition for the treatment of Y.
    2. Process for the preparation of a medicament for treating disease Y characterized in that compound X is used as the main active component of the medicament."

In terms of multiple dependent claims, rule 7 states that:

"Any claim which includes all the features of one or more other claims (claim in dependent form, hereinafter referred to as 'dependent claim') shall do so by a reference, if possible at the beginning, to the other claim or claims and shall then state the additional features claimed. Any dependent claim which refers to more than one other claim ('multiple dependent claim') shall refer to such claims in the alternative only. Multiple dependent claims shall not serve as a basis for any other multiple dependent claims."

Biotechnological inventions: guidelines on transgenic plants and animals

Rule 7 has also been amended to introduce guidelines on biotechnological inventions:

"For the purposes of these guidelines:

  1. 'biological material' means any material containing genetic information and capable of reproducing itself or being reproduced in a biological system;
  2. 'microbiological process' means any process involving or performed upon or resulting in microbiological material;
  3. 'biotechnological invention' are inventions which concern a product consisting of or containing biological material or a process by means of which biological material is produced, processed or used;
  4. 'genetic engineering' means the technology which manipulates gene recombination, cell fusion, etc. Inventions relating to genetic engineering include those of a gene or a DNA fragment, a vector, a recombinant vector, a transformant, a polypeptide or a protein, a fused cell, a monoclonal antibody, etc;
  5. 'plant variety' means any plant grouping within a single botanical taxon of the lowest known rank, which grouping, irrespective of whether the conditions for the grant of a plant variety right are fully met, can be –

    1. defined by the expression of the characteristics that result from a given genotype or combination of genotypes,
    2. distinguished from any other plant grouping by the expression of at least one of the said characteristics and,
    3. considered as a unit with regard to its suitability for being propagated and changed;
  6. a process for the production of plants or animals is essentially biological if it consists entirely of natural phenomena such as crossing or selection.

7bis. 2. Patentable Biotechnological Inventions

Biotechnological inventions shall be patentable if they concern –

  1. 'biological material' which is isolated from its natural environment or produced by means of a technical process even if it previously occurred in nature,
  2. 'plants or animals' provided that the technical feasibility of the invention is not confined to a particular plant or animal variety,
  3. ' a microbiological or other technical process', or a product obtained by means of such a process other than a plant or animal variety,

7bis. 3. Exceptions to Patentability of Biotechnological Inventions

ARIPO patents shall not be granted in respect of biotechnological inventions which, in particular, concern the following:

  1. processes for cloning human beings,
  2. processes for modifying the germ line genetic identity of human beings,
  3. uses of human embryos for industrial or commercial purposes,
  4. processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes,
  5. an embryonic stem cell of an animal, an animal at the various stages of its formation and development such as a germ cell, a zoosperm, an embryo, etc., belong to the category of animal variety,
  6. a single plant and its reproductive material (such as seed, etc.) which maintains its life by synthesizing carbohydrates and protein from the inorganic substances such as water, carbon dioxide and mineral salts and so on through photosynthesis belong to the category of plant variety,
  7. inventions that do not possess practical applicability, i.e. cannot easily be reproduced,
  8. the human body, at the various stages of its formation and development, and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot constitute patentable inventions."

Extensions of time limits

Rule 15 has been amended to provide for extensions of time limits. Such requests for extension must be in writing and the applicable fee must be paid. Where such a request is granted, the period of extension will be three months.

Divisional patent application

A specific provision for divisional applications has been introduced in rule 18. Any divisional application relating to any pending earlier ARIPO patent application must be filed at the ARIPO office.

Publication of ARIPO patent applications

Rule 19 introduces a period for publication of ARIPO patent applications, which will be as soon as possible after the expiry of 18 months from the date of filing or, if priority has been claimed, from the earliest date of priority.

Fee changes

A number of new fees have been introduced into the ARIPO Official Fee Schedule and a number of amendments have been made to existing fees.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions